America's Blood Centers®
It's About Life.

ABC NEWSLETTER

CURRENT EVENTS AND TRENDS IN BLOOD SERVICES

Visit ABC's Web site at: www.americasblood.org

2023 #29 **August 18, 2023**

INSIDE:

ABC Forms WELC and Council of States Initiatives

America's Blood Centers (ABC) recently introduced the formation of two new initiatives: the ABC Women's Executive Leadership Community (WELC) and the ABC Council of States. The WELC is a complimentary offering open to all employees of ABC member blood centers and industry partners. Through this imitative, ABC strives to empower leaders in the blood community through networking and professional development. WELC is the first of several programs planned within ABC's Executive Leadership Initiative, a key component of the ABC 2023-2026 Strategic Plan. By leveraging a diverse set of opinions and experiences, WELC drives action towards a supportive and inclusive blood community, benefiting individuals, employers, and ultimately the patients that rely on a safe and available blood supply. WELC will have virtual offerings to help build a diverse pipeline of leaders, creating a network where leaders feel supported.

ABC encourages individuals to join WELC and its LinkedIn Community, while sharing this information with those who may be interested.

The ABC Council of States has been developed to reflect the increasing importance of state-based advocacy as a wide variety of legislative and regulatory issues continue to impact community blood centers throughout the country. While ABC currently supports state-based advocacy through in-person workshops, a Coll*ABO*rate community, and bill tracking, the Council is a first-of-its kind initiative to convene member blood center representatives to conduct this work in a unified manner. Through the Council, ABC seeks to convene member blood centers to identify proactive state-based advocacy priorities, learn best practices, and monitor state legislation and regulations that impact community blood centers. This effort further amplifies the ongoing state-by-state lobbying activities and strategies of member blood centers, while demonstrating the power of our collective synergies and strength when we work together.

ABC plans to roll out this program in the fall with the first in-person meeting of the Council scheduled for the 2024 ABC Annual Meeting, March 4th-6th in Arlington, Va. Please contact ABC Chief Executive Officer Kate Fry, MBA, CAE with questions or feedback.

(Source: ABC MCN 23-072, 8/14/23)

An Update from Blood Bank of Hawaii Following the Maui Fires

America's Blood Centers (ABC) member Blood Bank of Hawaii (BBH) recently provided an update in the wake of the devastating fires in Maui. BBH President and Chief Executive Officer Kim-Anh Nguyen, MD, PhD explained in the August 15th communication that, "[f]irst of all, a big MAHALO to you, and my many friends from ABC member centers, for your texts and emails — your kind thoughts and positive energy have lifted us up during these days of crisis. [T]he fires on Maui are mostly, but not entirely extinguished: Kula (upcountry) fire is 60 percent contained, Lahaina fire was 85 percent contained, Kihei is 100 percent contained, and Kaanapali is extinguished. Over 2,200 structures have been damaged. Lahaina Harbor and Port are destroyed. Infrastructure, including schools, a medical clinic, and utilities have been burned to the ground…Large blood shipments were delivered to Maui [and] its supply [is]good. Plasma inventories were depleted [due to] several plasma exchanges in the days prior to the fire, followed by burn center utilization. We are grateful for the assistance from two brethren blood centers to replenish our plasma supply. Oahu donors responded with increased donations from Thursday to Sunday, but the numbers have begun to wane somewhat. BBH had just held a large drive on Maui in late July; our next planned return will be [in] November. Many BBH staff have family and friends who have been impacted, and it has been an emotionally difficult week…Moved by the unforgettable news footage, many of us would like to donate to the victims — water, clothing, and necessities. Unfortunately, these supplies are piling up throughout Oahu and may not make it to the shelters. The best way to help is to contribute money to organizations who are 'boots on the ground' and can best allocate resources directly to the victims, where it is most needed. Many charities have online giving options."

(Source: BBH Communication, 8/15/23)

REGULATORY NEWS

The U.S. Food and Drug Administration (FDA) published a final guidance on August 15th titled "Informed Consent Gudiance for [Institutional Review Boards] (IRBs), Clinical Investigators, and Sponsors." According to the agency, the guidance "supersedes FDA's guidance entitled "A Guide to Informed Consent," issued in September 1998, and finalizes FDA's draft guidance entitled "Informed Consent Information Sheet," issued in July 2014. This document is structured to first present general guidance on FDA's regulatory requirements for informed consent and a discussion of the roles of IRBs, clinical investigators, sponsors, and FDA related to informed consent, followed by a series of frequently asked questions."

(Source: FDA Gudiance, 8/15/23)

The *ABC Newsletter* (ISSN #1092-0412) is published by America's Blood Centers® and distributed by e-mail. Contents and views expressed are not official statements of ABC or its Board of Directors.

ABC advocates for and advances policies that promote the role of independent blood centers in providing life-saving blood products and recognizes the continuous need for a safe and robust blood supply. ABC exists to advocate for laws and regulations recognizing the essential role that independent blood centers play in the health care system; promote partnerships, policies, and programs that increase awareness about the need for blood donation; and serve as a thought leader in the advancement of evidence-based medical and scientific solutions related to health and safety.

America's Blood Centers
Chief Executive Officer: Kate Fry
Chief Medical Officer: Jed Gorlin
Editor: Mack Benton
Subscriptions Manager: Leslie Maundy
Annual Subscription Rate: $390

Send subscription queries to
memberservices@americasblood.org
America's Blood Centers
1717 K St. NW, Suite 900, Washington, DC 20006
Phone: (202) 393-5725
Send news tips to newsletter@americasblood.org.

BRIEFLY NOTED

A report from *Reuters* states that the American Red Cross "urged a federal judge to disregard a Justice Department 'statement of interest' that said the nonprofit is subject to the Sherman Act federal antitrust law and its checks against market power abuses." The filing comes in the wake of a lawsuit filed by Verax Biomedical Inc. earlier this year, as reported by *Bloomberg*, against the American Red Cross challenging the organization's [then] "new policy of pre-treating all platelets it sells to hospitals rather than letting them choose among various ways of ensuring platelet safety." An American Red Cross spokesperson told *Bloomberg Law* that "American Red Cross mitigates bacterial risk in platelets and complies with [U.S. Food and Drug Administration] guidance primarily by using pathogen inactivation, a solution that reduces bacterial risk while also mitigating other pathogen threats and safety risks. We believe pathogen inactivation is critical to maintaining a safe and readily available platelet supply for patients in need."

(Sources: *Reuters*, "American Red Cross spars with US Justice Dept over scope of antitrust law," 8/16/23; *Bloomberg Law*, "American Red Cross hit with antitrust suit over blood safety," 2/15/23)

RESEARCH IN BRIEF

Clinical Significance of IgM and IgG Isoagglutinins in ABO-Incompatible Solid Organ Transplantation. A manuscript in *Transfusion and Apheresis Science* focuses on ABO-incompatible (ABOi) solid organ transplantation, [which] "has been a valuable strategy for coping with organ shortages." The researchers explained that "[i]n Korea, 24.2 percent and 27.9 percent of the total living donor liver and kidney transplantation, respectively, is ABOi transplantation…For successful ABOi transplantation, the most important thing is to sufficiently reduce the antibodies (Ab) to the desired target level through various desensitization protocols while monitoring the ABO Ab levels." They noted that "a significant unresolved issue is whether monitoring should focus on immunoglobulin G (IgG) or immunoglobulin M (IgM) antibodies…Like other sugar chain-based antigens, IgG2 antibodies are a major component among IgG antibody subtypes, and IgG2 has low complement activation capacity." The authors stated that "[i]n ABOi transplantation, complement activation is the first mechanism by which ABO antibodies mediate rejection…Based on these points, the possibility of IgG ABO antibodies causing antibody-mediated rejection (AMR) appears to be theoretically rare." They explained that "[s]everal previous studies have reported evidence to support this theory…Therefore, based on these previous studies with clinical and experimental findings, it can be inferred that IgM antibodies may be considered more critical to assess ABOi transplantations than IgG…The situation of pregnancy can be considered as an alternate paradigm…Both pregnancy and transplantation share a similarity in that the tissues from different origins coexist through immunologic tolerance…ABO-incompatibility between mother and fetus causes no problem or mild hemolytic disease of the fetus and newborn (HDFN)." The researchers noted that "[t]his is because the mechanism by which maternal antibodies pass through the placenta to the circulation of fetus allows only the IgG antibody subtype to be transferred to the fetus…Therefore, considering IgG antibodies as a risk factor for ABOi transplantation failure is similar to a situation in which ABO-incompatibility induces HDFN…Whether ABO compatible or incompatible, transplantation always aims to be a risk-free process, but it is practically impossible to eliminate all immunological risks…Therefore, it is important to minimize immunological risk and keep it under a manageable level." The authors concluded that "it would be more important and efficient to focus on monitoring and managing IgM antibody level rather than IgG antibody level to assess the clinical graft status of ABOi solid organ transplant recipients."

Citation: Kim, H.J., Chung, Y., Kim, H., Dae-Hyun, K. "Clinical significance of IgM and IgG isoagglutinins in ABO-incompatible sold organ transplantation: insights from materno-fetal immunoglobulin status." *Transfusion Apheresis Science*. 2023.

Contributed by Richard Gammon, MD, Medical Director at OneBlood

America's Blood Centers®
It's About *Life.*

INSIDE ABC

The programs and services described in the Inside ABC section are available to ABC member blood centers and their staffs only, unless otherwise specified.

Register for the ABC Quality Forum Webinar

America's Blood Centers (ABC) will host its next Quality Forum Webinar on August 24th from 2-3 p.m. EDT. Registration is required for this event and a link is available to ABC members in MCN 23-071. The webinar will feature Kendra Reynolds, director of Quality and Regulatory Affairs at Innovative Blood Resources, presenting the basics of using the U.S. Food and Drug Administration's electronic submission process and providing helpful hints from her experiences using the system. Following the presentation, the audience will have an opportunity to ask questions and/or discuss their own experiences with the electronic submission process. Please contact us with questions.

(Source: MCN 23-071, 8/9/23)

UPCOMING ADRP Webinar: Spanish Donor Recruitment

Register today for the next ADRP webinar, titled "Spanish Donor Recruitment." This webinar will take place Wednesday, August 30th at 1 p.m. EDT and attendees will hear how their peers use creative marketing, donor service training, and translation services to create better experiences for their Spanish-speaking donors. Speakers include:

- Ramona Moise, director of Marketing at Gulf Coast Regional Blood Center;
- Liz Parker, training manager, Donor Services at Versiti; and
- Clinton McCoy, director of Mobile Donor Recruitment and Regional Operations at Carter BloodCare.

The webinar is free for ADRP members. Non-members may register for $25 and $50 for industry partners. Please contact us with questions.

(Source: ADRP Announcement, 8/2/23)

Register for the ADRP Masterclass: Change is Good — The Journey of Donor Eligibility

Registration is open for ADRP's Masterclass, "Change is Good — The Journey of Donor Eligibility," taking place September 20th-21st. While navigating changes in donor eligibility can feel overwhelming at times, this virtual conference is designed to equip industry professionals with invaluable insights, strategies, and best practices to confidently address such challenges and turn them into opportunities. This Masterclass is about more than just implementing a single deferral change. Instead, attendees will hear from award-winning leaders from outside the blood community. These speakers will share insights into building a culture that helps your blood center be more adaptable to future changes, tips for managing challenging conversations on and offline, and cutting-edge strategies being embraced across other industries so they can thrive in a challenging environment. Participants will also get the latest industry data, hear best practices, and be a part of thought-provoking conversations with industry peers.

PEOPLE

Robert Sanchez, MBA has been named president and chief executive officer at LifeStream Blood Bank effective September 18th. According to an announcement from the blood center, Mr. Sanchez is an, "Army Veteran with over 20 years of leadership experience serving in both the non-profit and for-profit healthcare sectors. He has held director and executive level positions in administration, donor services, marketing and public relations with independent blood centers and the American Red Cross. [Mr. Sanchez] previously served as the vice president [of the] Central United States and the president of the Northeast Business Unit for Biomat USA, Grifols. He holds a Bachelor of Science [degree] in Management and a Master of Business Administration [degree]. [Mr. Sanchez] will be the 6th President and CEO in LifeStream's 72 years as an independent blood center serving the Southern California community." He succeeds Rick Axelrod, MD, MBA who retired in June.

(Source: LifeStream Blood Bank Annoucement, 8/17/23)

WORD IN WASHINGTON

The Biomedical Advanced Research and Development Authority (BARDA) announced that it is seeking "to establish a partnership with a Consortium Management Firm (CMF) to facilitate and expedite the establishment and administration of the BioMaP-Consortium." According to the BARDA announcement, "[t]he BioMaP-Consortium will bring together industry partners across the drug and vaccine manufacturing supply chains, including the manufacturers of required raw materials, consumables and fill-finish services suppliers." The stated goal of the consortium will be to "expand domestic manufacturing capabilities by creating a mechanism for fast and flexible access to commercial biopharmaceutical manufacturing platforms and innovative technologies which can transition rapidly to respond to future public health emergencies…The BioMaP-Consortium will be an acquisition vehicle designed to strengthen and enhance biopharmaceutical manufacturing capabilities by establishing partnerships with industry across three key domains:

- Industrial Base Expansion of Biomanufacturing Supply Chain;
- Biomanufacturing Capacity Expansion and Reservation; [and]
- Advanced Biomanufacturing Technologies."

The call for submissions has been issued with a deadline of 3 p.m. EDT on August 22nd.

(Source: BARDA Announcement, 8/4/23)

The U.S. Food and Drug Administration (FDA) will hold a virtual meeting on September 6th from 1-3 p.m. EDT titled, "Understanding FDA Inspections and Data." According to the agency, the meeting will "provide an overview of drug manufacturing inspections. Participants will gain a general understanding of Current Good Manufacturing Practices (CGMPs) and FDA Inspections. FDA subject matter experts will also demonstrate where inspection data is found on FDA's website and share how to navigate the FDA Inspection Dashboard. Registration is open as the meeting is designed for regulatory science and regulatory affairs professionals, along with healthcare organizations that purchase pharmaceuticals."

(Source: FDA Announcement, 8/10/23)

GLOBAL NEWS

The Pan American Health Organization (PAHO) led a meeting this week to "discuss increasing the use of tools to detect and monitor mosquito-borne diseases in the Americas." According to the organization, infections of arboviruses are on the rise in the region of the Americas. "From the beginning of 2023 until the end of July, more than 3 million new dengue infections and more than 324,000 cases of chikungunya were reported in the Americas. With 27,000 cases across the region in the same period, Zika has a lower incidence rate, while sporadic cases of yellow fever represent a permanent risk of re-emergence of this potentially lethal disease." Sylvain Aldighieri, deputy director of PAHO's Department of Health Emergencies, added in a statement from PAHO, "at least nine arboviruses with public health impact - such as dengue, zika, chikungunya and yellow fever - are circulating in Latin America and the Caribbean, so strengthening and expanding laboratory detection and surveillance capacities are key to ensuring a timely response to outbreaks and epidemics." Arboviruses are carried and transmitted by bites from arthropods such as mosquitoes and ticks.

(Source: PAHO Announcement, 8/16/23)

The Medicines and Healthcare products Regulatory Agency (MHRA) has published data supporting the use of UK plasma for the manufacture of albumins and variant Creutzfeldt Jakob Disease(vCJD) risk. In June, Regulators in the United Kingdom (UK) lifted a ban that prevented UK-source plasma from being used to manufacture albumin. The MHRA concluded in their findings that, "[o]verall, from the perspective of vCJD safety, considering the totality of the collected evidence, such as existing manufacturing and process capability, the most recent epidemiological data, expert advice, and having regard to previous reviews examining vCJD safety performed by the MHRA, it was concluded that UK-sourced plasma can be used for the manufacture of albumin medicinal products, in addition to the already approved use for the manufacture of immunoglobulins."

(MHRA Announcement, 8/15/23)

COMPANY NEWS

Excision BioTherapeutics, Inc. announced the publication of data in *Gene Therapy* that demonstrates their investigational gene therapy "safely removes the simian form of HIV from the genomes of non-human primates." According to a company news release, "researchers treated non-human primates with a single intravenous injection of [the investigational gene therapy] at one of four different dose levels. Necropsy and tissue analyses were carried out at three or six months after the start of treatment. Data were collected on the biodistribution, histopathology, and gene editing of the EBT-001 in blood and tissues representing sites of viral latency, including lymph node and spleen tissue, as well as other tissues. Data were also collected to assess safety, which included off-target analyses at the different dose levels. Analyses showed that EBT-001 was broadly distributed throughout the tissues analyzed in a dose-dependent manner and evidence of gene editing of SIV proviral DNA was observed in all significant viral reservoirs. EBT-001 was well-tolerated at all dose levels, with no evidence of toxicity in clinical examination of the animals or following histopathological investigation." The investigational gene therapy is currently undergoing evaluation in first-in-human phase I/II clinical trials and received the U.S. Food and Drug Administration's (FDA) Fast Track Designation last month.

(Source: Excision BioTherapeutics News Release, 8/17/23)

(continued on page 7)

COMPANY NEWS (continued from page 6)

Janssen Pharmaceutical Companies of Johnson & Johnson has been granted "accelerated approval [for] TALVEY™, a first-in-class bispecific antibody for the treatment of adult patients with relapsed or refractory multiple myeloma who have received at least four prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 antibody." The approval is based on results from the talquetamab Phase II MonumenTAL-1 study, which "evaluated the efficacy of TALVEY™ in participants with relapsed or refractory multiple myeloma at the recommended Phase II dose(s), established at SC 0.4 mg/kg weekly and 0.8 mg/kg every two weeks, respectively. Efficacy was based on overall response rate and duration of response." According to the company news release, TALVEY™ "binds to the CD3 receptor on the surface of T cells and G protein-coupled receptor class C group 5 member D expressed on the surface of multiple myeloma cells, non-malignant plasma cells and healthy tissue such as epithelial cells in keratinized tissues of the skin and tongue."

(Source: Janssen Pharmaceutical Companies News Release, 8/10/23)

Valneva SE announced the FDA moved the expected Prescription Drug User Fee Act (PDUFA) action date for the company's biologics license application (BLA) for its investigational chikungunya virus vaccine candidate. The new date is the end of November as FDA had previously expected to finish its review of the BLA by the end of August. Valneva SE indicated in a news release that the "FDA extended the PDUFA date to allow sufficient time to align and agree on the phase 4 program necessary under the accelerated approval pathway. No additional clinical data have been requested for the approval process."

(Source: Valneva SE News Release, 8/14/23)

Upcoming ABC Webinars & Virtual Events – Don't Miss Out!

- **ABC Quality Forum Webinar** – Aug. 24. More information available to ABC Members, including a link to registration, in MCN 23-071.
- **ADRP: The Association for Blood Donor Professionals Spanish Donor Recruitment Webinar** – Aug 30. Registration is open. More information available here.
- **ADRP Masterclass: Change Is Good – The Journey of Donor Eligibility** – Sept. 20-21. Registration is open. More information available here.

CALENDAR

Note to subscribers: *Submissions for a free listing in this calendar (published weekly) are welcome. Send information to newsletter@americasblood.org. (For a more detailed announcement in the weekly "Meetings" section of the newsletter, please include program information.)*

2023

Aug. 24. **ABC Quality Forum Webinar.** More information available to ABC Members, including a link to registration, in MCN 23-071.

(continued on page 8)

CALENDAR (continued from page 7)

Aug 30. **ADRP Webinar: Spanish Donor Recruitment.** Registration is open. More information available here.

Aug. 30. **U.S. Food and Drug Administration's (FDA) Center for Biologics Evaluation and Research (CBER) Officer of Therapeutic Products (OTP) Town Hall: Nonclinical Assessment of Cell and Gene Therapy Products (Virtual).** More information available here.

Sept. 6. **FDA Meeting: Understanding FDA Inspections and Data (Virtual).** Registration is open. More information available here.

Sept. 7-9. **European Blood Alliance European Conference on Donor Health and Management. Vienna, Austria.** Registration is open. More information available here.

Sept. 17-20. **American Association of Tissue Banks Annual Meeting, National Harbor, Md.** Registration is open. More information available here.

Sept. 20-21. **ADRP Masterclass: Change Is Good – The Journey of Donor Eligibility (Virtual).** Registration is open. More information available here.

Sept. 20. **The Department of Transfusion Medicine, National Institutes of Health (NIH) Clinical Center, NIH, and the American Red Cross 42nd Annual Immunohematology and Blood Transfusion Symposium.** Registration is open. More information available here.

Oct. 9-11. **Advanced Medical Technology Association (AdvaMed) The MedTech Conference, Anaheim, Calif.** Registration is open. More information available here.

Oct. 14-17. **AABB Annual Meeting, Nashville, Tenn.** Registration is open. More information available here.

Oct. 18-20. **American Society for Clinical Pathology (ASCP), Long Beach, Calif.** More information available here.

Nov. 18-21. **ISBT Regional Congress, Cape Town, South Africa.** Registration is open. More information available here.

2024

Feb.7-8. **International Plasma and Fractionation Association & EBA Symposium on Plasma Collection and Supply. Leiden, Netherlands.** More information available here.

Mar. 4-6. **ABC Annual Meeting, Arlington, Va.** More information available here.

May 15-17. **2024 ADRP Annual Conference, St. Louis, Mo.** More information available here.

CLASSIFIED ADVERTISING

Classified advertisements, including notices of positions available and wanted, are published free of charge for a maximum of three weeks per position per calendar year for ABC members. There are charges for non-members: $139 per placement for *ABC Newsletter* subscribers and $279 for non-subscribers. A six (6) percent processing fee will be applied to all credit card payments. Notices ordinarily are limited to 150 words. To place an ad, e-mail: newsletter@americasblood.org

POSITIONS

Transfusion Lab Supervisors Needed! Join Florida's leading blood bank, OneBlood, as a Lab Supervisor working inside one of the largest hospitals in Tampa, FL. Bring your leadership, technical expertise, and management experience to support the transfusion testing procedures on patient and/or donor samples. Qualified candidates should possess three (3) or more years' experience in a clinical laboratory, preferably blood banking environment, including one (1) or more years' experience in supervision and management experience, as well as a valid and current Florida Clinical Laboratory Technologist license in Immunohematology or Blood Banking; Supervisor license strongly preferred. To apply and view a complete Job Description of this position, visit: www.oneblood.org/careers. OneBlood, Inc. is an Equal Opportunity Employer/Vet/Disability.

(continued on page 9)

POSITIONS (continued from page 8)

Manager of Technical Services. The Blood Connection is seeking a proactive and results-driven Manager of Technical Services to oversee and manage the daily operations within our technical departments which include Hospital Services, Biologics Processing, and Reference Laboratory. This position requires an understanding of laboratory operations, including specialist (SBB) skills, and involves supervising staff while performing essential functions within the laboratory. The ideal candidate will hold their SBB and have a background in the Reference Laboratory. This role is based in Morrisville, NC. Prospective candidates may be eligible for relocation assistance. How to apply: Manager of Technical Services Application.

Fairbanks Center Manager. The Blood Bank of Alaska (BBA) is looking for a Fairbanks Center Manager. The Fairbanks Center Manager is responsible for oversight and coordination of the daily operational collection functions and related product processing workflow for the BBAF Center. Directs the activities of such team to facilitate reaching and exceeding goal. Oversight and partnership with BBA management team in planning, program formulation, and technical decision making with particular reference to the role, functions, and operation of the blood bank's technical areas. This position is full-time exempt. The Blood Bank of Alaska offers competitive wages and an exceptional benefits plan. We offer medical, dental, vision, life, and short/long term disability programs to qualified employees. Educational assistance, paid annual leave and holidays, and a 401 (k) program are also available. The Blood Bank is an equal opportunity employer. Qualified applicants are considered for employment without regard to race, color, religion, national origin, age, disability, marital/veteran status, or any other legally protected status. Interested candidates please apply online at https://bloodbankofalaska.apscareerportal.com.

Director of Hospital Services and Manufacturing. The Blood Bank of Alaska is looking for a Director of Hospital Services and Manufacturing. The Director of Hospital Services and Manufacturing is responsible for ensuring alignment of teams with organizational goals and compliance with regulatory guidelines. Participates as a member of the blood bank's management team in planning, program formulation and decision making with reference to the role, functions and technical support of the manufacturing and distribution of blood products. Fosters and enhances customer hospital relations. This person ensures a dedicated focus on the production and distribution of quality products in a timely manner while providing the highest level of customer service. Also ensures all procedures are followed and promotes a positive work environment. This position is full-time exempt. The Blood Bank of Alaska offers competitive wages and an exceptional benefits plan. We offer medical, dental, vision, life, and short/long term disability programs to qualified employees. Educational assistance, paid annual leave and holidays and a 401 (k) program are also available. A $1,500 retention bonus will be paid after one year of service with the Blood Bank of Alaska. The Blood Bank is an equal opportunity employer. Qualified applicants are considered for employment without regard to race, color, religion, national origin, age, disability, marital/veteran status, or any other legally protected status. Interested candidates please apply online at https://bloodbankofalaska.apscareerportal.com.

Quality Systems Specialist and Technical Writer. The Blood Bank of Alaska is looking for a Quality Systems Specialist and Technical Writer. The person in this role is responsible for promoting organizational compliance with accrediting agency, state, and federal regulations. Managing the Blood Bank of Alaska's occurrence program which includes performing investigations for occurrences. The Quality Systems Specialist and Technical Writer writes, revises, edits, and approves Standard Operating Procedures (SOPs) along with assisting document owners in writing and revising SOPs. Assists in the management of the Blood Bank of Alaska's document control process and ensures consistency across departments when policies or procedures change. This position is full-time non-exempt. The Blood Bank of Alaska offers competitive wages and an exceptional benefits plan. We offer medical, dental, vision, life, and short/long term disability programs to qualified employees. Educational assistance, paid annual leave and holidays, and a 401 (k) program are also available. A $1,500 retention bonus will be paid after one year of service with the Blood Bank of Alaska. The Blood Bank is an equal opportunity employer. Qualified applicants are considered for employment without regard to race, color, religion, national origin, age, disability, marital/veteran status, or any other legally protected status. Interested candidates please apply online at https://bloodbankofalaska.apscareerportal.com.

Laboratory Services Manager. The Blood Bank of Alaska is looking for a Laboratory Services Manager. Under the general direction of the Director of Laboratory Services, this person is responsible for oversight of daily laboratory operations ensuring that laboratory product QC and donor test results meet CLIA, AABB and FDA compliance standards/regulations for the manufacture of blood products. The Laboratory Services Manager is also responsible for oversight of laboratory personnel. This position is full-time exempt. The Blood Bank of Alaska offers competitive wages and an exceptional benefits plan. We offer medical, dental, vision, life, and short/long term disability programs to qualified employees. Educational assistance, paid annual leave, and holidays and a

(continued on page 10)

POSITIONS (continued from page 9)

401 (k) program are also available. A $1,500 retention bonus will be paid after one year of service with the Blood Bank of Alaska. The Blood Bank is an equal opportunity employer. Qualified applicants are considered for employment without regard to race, color, religion, national origin, age, disability, marital/veteran status, or any other legally protected status. Interested candidates please apply online at https://bloodbankofalaska.apscareerportal.com.